A ging is associated with the development of both osteoporosis and vascular disease, and there is increasing evidence for a link between bone metabolism and the vasculature. 1 A number of cross-sectional and longitudinal studies have demonstrated inverse, independent associations between bone mineral density and vascular calcification, [2] [3] [4] [5] which appear to be predictive of atherosclerosis and related cardiovascular risk. 6 In addition, low bone mineral density has been associated with increases in the risk of cardiovascular events in prospective studies. 3 Of interest, high bone turnover itself is associated with increased cardiovascular mortality in elderly subjects independently of age, sex, overall health, serum parathyroid hormone levels, and hip fracture status. 7 This raises the interesting and important question of possible underlying mechanisms that may be driving bone loss, vascular disease, and/or calcification. Inflammation and oxidative stress represent a common soil for osteoporosis and atherosclerosis and might explain the coincidence of these diseases. 8, 9 Researchers are also investigating the existence of a causal connection between bone and vascular diseases. These studies are focusing mainly on the osteoprotegerin/ receptor activator of nuclear factor-B (RANK)/RANK ligand triad, the plasma fetuin-A mineral complexes/calciprotein particles, fibroblast growth factor-23/Klotho axis, and circulating calcifying cells (Table 1 ).
In mice, the lack of osteoprotegerin, an inhibitor of osteoclast maturation, is followed by the development of both osteoporosis and vascular calcification. 10 The original finding suggested a central role for dysregulation in the osteoprotegerin/RANK/RANK ligand triad in the pathobiology of the bone-vascular axis. However, despite a series of studies showing direct biological effects of osteoprotegerin on vascular cells, there is no definitive demonstration that prevention of arterial calcification by osteoprotegerin is independent of actions on bone resorption. Indeed, several studies report reduced vascular calcification in animals treated with antiresorptive drugs, 11 whereas the antiatherosclerotic statins may improve bone mineral density. 12 Fibroblast growth factor-23 is a bone hormone that promotes phosphate excretion and inhibits vitamin D biosynthesis in the kidney. Klotho, which acts as both a membraneassociated protein and a secreted mediator, is responsible for the kidney-specific action of fibroblast growth factor-23. 13 In mice, deletion of Klotho leads to accelerated aging, with osteopenia and extensive vascular calcification. 14 Although hyperphosphatemia is implicated in most of the vascular changes observed in Klotho and fibroblast growth factor-23null mice, 15 additional studies are needed to dissect the contribution of fibroblast growth factor-23 and Klotho in the bone-vascular axis.
Circulating calciprotein particles also offer an interesting link between bone metabolism and arterial calcification. 16 Fetuin-A, a plasma protein synthesized by the liver, allows persistence in the solution of circulating minerals, preventing their ectopic deposition, but is also central for serum-driven calcification of type I collagen. 17 Of note, increased circulating levels of calciprotein particles are observed in animal models of renal failure and can be reduced by treatment with bisphosphonates. 18 However, how calciprotein particles are affected by bone remodeling and how they are cleared from the circulation are poorly understood.
Finally, after the discovery of circulating calcifying cells, 19 clinical studies investigated the role of these cell types in the link between osteoporosis and vascular calcification. 20 An increased number of circulating osteogenic cells was also observed in the osteoporotic osteoprotegerin-null mice, which correlated with the amount of calcium in the vessels. 21 Emerging data consistently indicate that circulating calcifying cells are involved in both bone and vascular disease, but several, likely interrelated, phenotypes have been identified. Here, we review the phenotypic/biological characteristics of circulating calcifying subpopulations of the cells identified so far. Before describing these cells, we discuss the rationale and evidence suggesting that extraparietal cells can be actively involved in vascular calcification. Finally, we look at the evidence for a role of circulating calcifying cells in the bone-vascular axis that has stimulated the use of these cells for tissue engineering and bone repair.
The Role of Extraparietal Cells in Vascular Calcification
For decades, vascular calcification has been considered a passive, unavoidable phenomenon, intrinsically connected with aging and atherosclerotic vascular degeneration. This view is now challenged by emerging knowledge about the mechanisms and clinical importance of calcium deposition in the vascular system. Although the impact of extensive coronary calcification on plaque stability is still debated, spotty neointimal calcifications are likely to increase lesion vulnerability and probability of rupture. 22, 23 Additionally, calcium accumulation in the cardiac valves and large arteries is accompanied by adverse outcomes. 24 -26 In particular, arterial calcification causes a progressive reduction in vascular resilience and compliance with a parallel increase in arterial stiffness, which is a major determinant of the rise in systolic blood pressure, the fall in diastolic blood pressure, and the acceleration of pulse-wave velocity. 27, 28 These hemodynamic alterations increase left ventricular load and the susceptibility to myocardial ischemia. 29, 30 A series of clinical and basic science studies performed in the last several years underscored the biological complexity of the processes driving ectopic mineralization. 31 Resident vascular cells produce local mediators (such as pyrophosphate and matrix-gla protein) that, in cooperation with circulating factors (ie, fetuin-A), protect the arteries from deposition and growth of minerals. 16, 32, 33 On the other side, cell death-related processes, together with the bone-like activity of vascular cells, stimulate ectopic calcification. 34, 35 The demonstration that bone markers/transcription factors are expressed within calcified atherosclerotic plaques suggests that osteogenic programs are activated during vascular mineralization. In addition, cell types showing morphological and biological features close to chondrocyte/osteoblast-like cells have been identified in both mouse models of atherosclerosis and human atherosclerotic samples. 36, 37 These cells might originate from mesenchymal progenitors resident in the vascular wall, from transdifferentiation of mature vascular smooth muscle cells (SMCs), or from circulating cells harboring a calcifying potential. Several studies have shown that, under appropriate stimuli (such as hyperphosphatemia, inflammation, and oxidative stress), SMCs differentiate into osteoblast/chondrocyte-like cells. 31, 38 Other studies have demonstrated the presence of mesenchymal-derived progenitor cells in the vessel wall, including microvascular pericytes, which retain an osteochondrogenic potential. 39, 40 The recent identification of circulating calcifying cells raises the interesting question of whether these cell types should be added to the list of vascular calcification promoters.
Atherosclerotic lesions in mice are usually characterized by the presence of cartilaginous metaplasia, with chondrocyte-like cells actively depositing calcium within the advanced plaque. 36 Speer et al 41 investigated the origin of these cells by using a lineage-tracing strategy in the matrixgla protein-null mouse, a model of medial calcification. They elegantly demonstrated that chondrocyte-like cells in calcified vessels originated from transdifferentiation of resident SMCs and not from green fluorescent protein-positive (GFP ϩ ) cells used to reconstitute the bone marrow (BM) of matrix-gla protein-deficient mice. More recently, however, Doehring et al 42 showed a significant contribution of BM-derived myeloid CD34 ϩ CD13 ϩ cells to the population of chondrocyte-like cells observed in the intimal lesions of low-density lipoprotein-null mice. A significant number of BM-derived cells present in the plaques expressed the chondrogenic marker type II collagen. In addition, the majority of these cells were CD34 ϩ , and Ͼ50% expressed the myeloid marker CD13. 42 Although the calcifying potential of these BM-derived cells was not clearly established, these 2 studies suggest a differential origin of chondrogenic cells involved in intimal versus medial calcification, with most of the medial cells originating from transdifferentiation of SMCs and BMderived cells contributing to chondrocyte-like cells recruited into the intimal atherosclerotic plaques.
Similar to arterial cells, aortic interstitial valve cells display phenotypic heterogeneity in terms of calcifying potential. 43, 44 Of interest, BM transplantation studies demonstrated a significant participation of BM-derived cells in normal valve homeostasis. In particular, Visconti et al 45 demonstrated that BM-derived cells can enter the native valve and differentiate into cells similar to resident interstitial valve cells. Subsequently, the same group showed that BMderived cells found in the normal postnatal valve exhibited a myeloid (CD45 ϩ CD11c ϩ MHCII ϩ F4/80 Ϫ ) or progenitorlike (CD45 ϩ CD133 ϩ Hsp47 ϩ ) profile. 46 However, the actual contribution of these cells to pathological valve remodeling is currently unknown. Of note, a BM transplantation study in Table 1 
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senile apolipoprotein E-null mice with calcific aortic stenosis showed that BM-derived cells expressing osteoblast-related proteins (osteopontin and osteocalcin [OC]) could be identified near the site of ectopic calcification. 47 This finding is in agreement with the recent observation of CD45 ϩ OC ϩ Col1 ϩ cells within calcified human leaflets. 48 Although BM-derived CD31 ϩ cells have not been observed in the valvular endocardium of normal leaflets, 46 a significant number of GFP ϩ CD31 ϩ cells were described in the stenotic valve of transplanted apolipoprotein E-deficient mice. 47 Therefore, even if endothelial cells of BM origin seem not to participate in normal valve homeostasis, it cannot be excluded that circulating endothelial progenitors might instead be recruited to the diseased valve and undergo differentiation into chondroblast/osteoblast-like cells. A recent study conducted in mitral valves showed that a specific subpopulation of endothelial valve cells retain a chondrogenic and osteogenic differentiation potential and might represent a local reservoir of interstitial valve cells progenitors. 49 The relative contribution of local endothelial valve cells progenitor cells versus circulating endothelial progenitor cells (EPCs) to valve calcification represents an interesting field of research. Taken together, an increasing amount of data in animal models of vascular/valve disease, confirmed by histopathological studies on human samples, highlights the potentiality of BM-derived cells to engraft into the pathological tissue and to participate in the calcification processes. Below, we provide a detailed review of circulating cell phenotypes that may contribute to vascular calcification and/or regulation of the bone/vascular axis.
Circulating Mesenchymal Osteoprogenitor Cells
Osteoblast precursors are traditionally considered to reside in the BM mesenchymal stem cell (MSC) compartment. Increasing evidence indicates the existence of circulating osteoblastic cells, called circulating osteoprogenitors, 19, 50, 51 that appear to be made of 2 populations: 1 related to hematopoietic stem cells/EPCs and the other to plastic-adherent marrow stromal cells/MSCs. MSCs are traditionally isolated in ex vivo cultures from the low-density mononuclear fraction of BM by adherence to plastic surfaces. 52 Using this approach, a number of groups have identified MSC-like cells with osteogenic potential in peripheral blood. [53] [54] [55] [56] For example, Kuznetsov et al 55 identified circulating adherent, clonogenic, fibroblast-like cells with osteogenic and adipogenic potential from the blood of 4 mammalian species (mouse, rabbit, guinea pig, and human). These cells were osteonectin positive, osteopontin positive, collagen 1 positive, ␣-smooth muscle actin positive, and negative for the expression of hematopoietic and endothelial markers. Interestingly, however, the human blood-derived adherent cells were negative for Stro-1, endoglin, and Muc-18, all of which are expressed by human BM MSCs, suggesting important differences between BM and peripheral blood MSC-like populations. In addition, the frequency of these cells, especially in humans, was extremely low (Ͻ1/10 6 cells). Nonetheless, the MSCs derived from peripheral blood were able to form mineralized nodules in vitro and bone in an in vivo transplantation assay.
Consistent with the findings of Kuznetsov, 55 Zvaifler et al 54 isolated MSC-like cells from peripheral blood of humans using an elutriation procedure. After 7 to 14 days, cultures of these cells contained both fibroblast-like cells and a small population of large round cells. The cultured cells were negative for the hematopoietic/endothelial markers CD45, CD14, and CD34 and positive for SH2 (CD105, endoglin), vimentin, collagen 1, and bone morphometric protein (BMP) receptors 1A and II. Interestingly, Stro-1 was expressed in the large cells. Several investigators have examined conditions under which MSCs could be mobilized into peripheral blood, presumably from the BM. Thus, Fernandez et al 53 found that administration of granulocyte colony-stimulating factor or granulocyte macrophage colony-stimulating factor to human subjects (traditionally used to mobilize hematopoietic stem cells) also resulted in the mobilization of MSCs. Using a rat model, Rochefort et al 57 found that the circulating MSC pool increased dramatically (by Ϸ15-fold) when the animals were exposed to long-term hypoxia. In contrast to granulocyte colony-stimulating factor or granulocyte macrophage colonystimulating factor administration to humans, however, hypoxia-induced mobilization appeared to be specific for MSCs because total circulating hematopoietic progenitor cells were not significantly increased.
In subsequent studies, Otsuru and colleagues 58 examined how circulating MSC-like cells contributed to osteogenesis in a BMP-induced model of ectopic bone formation. After lethal-dose irradiation and subsequent GFP-BM cell transplantation in mice, a BMP-2-containing collagen pellet was implanted into muscle. Three weeks later, these investigators found a significant number of GFP-positive osteoblastic cells in the newly generated ectopic bone, suggesting that BMP-2 may be another factor leading to the mobilization of MSCs from BM. In a subsequent study, the same group characterized the BMP-2-mobilized circulating MSCs as negative for expression of hematopoietic (CD45, CD11b, Gr-1) and endothelial (CD34, Flk-1, CD31) markers but positive for expression of the mesenchymal marker, CD44, and for CXCR4, a receptor for the chemokine stromal cell-derived factor-1, which regulates stem cell trafficking. 59 Interestingly, expression of stromal cell-derived factor-1 was markedly increased in vascular and osteoblastic cells in and around the BMP-2 implant, suggesting that BMP-2-induced stromal cell-derived factor-1 expression was responsible, at least in part, for the mobilization of MSCs into peripheral blood.
In a more recent study, Alm and colleagues 60 examined the presence of circulating MSCs in fracture patients. They studied 3 patient groups: elderly women with a femoral neck fracture treated with cemented hemiarthroplasty, an ageand sex-matched group with hip osteoarthritis treated with cemented total hip arthroplasty, and young adults with surgically treated lower-extremity fractures. Criteria for identifying circulating MSCs included cell surface markers (CD105 ϩ , CD73 ϩ , CD90 ϩ , CD45 Ϫ , CD14 Ϫ ), proliferation through several passages, and osteogenic, chondrogenic, and adipogenic differentiation. They reported that plasticadherent MSCs were found in the peripheral blood from 22% of hip fracture patients, 46% of younger fracture patients, and in none of the hip osteoarthritis patients, suggesting that mobilization of MSCs into the circulation occurs in response to fracture, even in elderly patients. These findings were also consistent with previous work by Eghbali-Fatourechi et al 19 showing that circulating cells expressing OC increased markedly after fracture, although the circulating osteoprogenitor cells identified in this study likely included cells of both hematopoietic and mesenchymal origin.
Circulating Calcifying CD34 ؉ Progenitor Cells and EPCs
The hematopoietic system is hierarchically composed of multipotent stem cells, lineage-committed and -restricted progenitors, which give rise to terminally differentiated cells. 61 EPCs were originally identified as BM-derived progenitors committed (not restricted) to the endothelial lineage and able to take part in endothelial repair and neoangiogenesis. 62 A huge amount of data has accumulated on EPC identity and function in relation to diagnostic, prognostic, and therapeutic uses (see the work by Alm and colleagues 60 for a review). The research has been dampened, however, by the elusive phenotype and ambiguous definition of EPCs. 63, 64 Some authors have questioned the actual role played by endogenous EPCs, 65, 66 and it has been recognized that several putative EPC phenotypes differ in lineage origin and function. 63, 64 True EPCs are supposed to derive from hemangioblasts recapitulating developmental differentiation steps. Provided that an adult counterpart of the embryonic hemangioblast exists, EPCs descending from this lineage should express hematopoietic stem cell (such as CD34 and CD133) and endothelial (such as vascular endothelial growth factor receptor-2, KDR) markers. When EPCs are isolated from circulating mononuclear cells, short-term culture gives rise to monocytic early EPCs, whereas long-term culture yields late EPCs, which are almost indistinguishable from proliferating mature endothelial cells. 64 The population of c-Kit-positive, Sca-1-positive, lineage marker-negative (KSL) cells in the mouse BM 67 is believed to be a source of EPCs, which differentiate into endothelial cells and contribute to vasculogenesis. 68 -70 A human-equivalent population is composed of peripheral blood CD34 ϩ cells, which reportedly contain EPCs and hematopoietic stem cells 71 and promote vasculogenesis. 62, 71 Several reports have shown that CD34 ϩ cells are committed not only to endothelial cells but also to mural perivascular cells (ie, pericytes and smooth muscle cells). [72] [73] [74] For instance, Zengin et al 75 reported the existence of progenitor and stem cells in a distinct zone between the smooth muscle and the adventitial layer of human adult vascular wall that are capable of differentiating into mature endothelial cells, as well as hematopoietic and local immune cells. These findings indicate that BM progenitors are heterogeneous populations potentially committed to multilineage cell types besides the hematopoietic ones. Several lines of evidence indicate that CD34 ϩ cells and EPCs, either in the bloodstream or in culture, are reduced in patients at risk for or with established cardiovascular disease, 63, 76 and this is considered to promote vascular disease initiation or progression. Circulating progenitors not only are reduced in cardiovascular disease patients but also display an altered differentiation potential, with impaired generation of endothelial cells and a higher yield of inflammatory and smooth muscle-like cells. 77, 78 Along this line of investigation, recent data have demonstrated that circulating CD34 ϩ progenitor cells and CD34 ϩ KDR ϩ EPCs can also express bone-related proteins, especially OC and/or bone alkaline phosphatase (BAP). 79, 80 OC is a noncollagenous bone protein implicated in bone mineralization and calcium homeostasis; BAP is a glycoprotein found on the surface of osteoblasts, and its function is essential to the mineralization process. Similarly, previous reports showed that CD34 ϩ and CD133 ϩ cells were capable of differentiating into osteoblasts and hematopoietic and endothelial cells in vitro. 81, 82 Because securing an adequate blood supply to bone fracture sites is crucial for bone healing, an emerging focus in regenerative medicine is to foster progenitor cells for simultaneous neoangiogenesis and bone healing. EPCs are appealing for this task because studies on the link between angiogenesis and the bone growth have led to the discovery of a developmental reciprocity between endothelial cells and osteoblasts in vitro. Therefore, a series of studies have explored the use of peripheral blood CD34 ϩ cells or EPCs for bone fracture healing. [83] [84] [85] [86] Using a mouse bone fracture model, these studies first confirmed that fractures trigger EPC mobilization and incorporation into fracture sites. 83 The overlapping origin of endothelial and osteogenic markers was confirmed by Matsumoto et al, 84 who showed that Ϸ20% of human peripheral blood CD34 ϩ cells expressed the mRNA for OC. To investigate the clinical feasibility of peripheral blood CD34 ϩ cells for bone healing, the authors demonstrated that human peripheral blood CD34 ϩ cells recruited to the fracture site after systemic delivery developed a favorable environment for fracture healing by enhancing vasculogenesis/angiogenesis and osteogenesis and finally led to functional recovery from fractures. 84 Moreover, seeding the femoral nonunion site of immunodeficient rats with mobilized human CD34 ϩ cells promoted successful fracture union. 85 Importantly, CD34 ϩ cells were more effective than mononuclear cells in inducing fracture healing, suggesting that stem/progenitor cell properties were involved. 86 After these series of studies, researchers demonstrated fracture-induced mobilization of EPCs for bone healing in mice, rats, and humans. [87] [88] [89] EPCs were also reported to contribute to bone healing in rat segmental bone defect model and critically sized bone defects in sheep. 90 -92 Although CD34 ϩ and CD133 ϩ cells have the potential to differentiate into osteoblast-like cells, EPCs are believed to sustain bone healing mainly through improving vascularity, although a procalcific differentiation capacity of EPCs has also been shown. From a pathophysiological point of view, the combined vascular and bone tropism of EPCs may be important in the bone-vascular axis. Indeed, several preclinical studies and preliminary clinical evidence indicate that EPCs home to sites of vascular damage. 93, 94 Therefore, an osteogenic differentiation of these cells may be involved in the process of vascular calcification. Gossl et al 80 found that OC expression on circulating EPCs was significantly associated with coronary artery disease in a cohort of 72 patients undergoing invasive coronary assessment. The percentage of OC expression on CD34 ϩ KDR ϩ EPCs was inversely corre-lated with serum matrix-gla protein, an inhibitor of calcification. They also showed that the culture of CD34 ϩ cells (as the EPC-generating population) in osteogenic conditions led to the formation of mineralized structures and upregulation of bone-related genes. Subsequently, by performing blood sampling from the proximal aorta and the coronary sinus in patients undergoing catheterization, the same group demonstrated that OC-expressing EPCs are retained in the coronary circulation of patients with coronary endothelial dysfunction, providing indirect evidence in support of homing of these procalcific cells at sites of vascular damage. 79 The relationship between the osteogenic and the endothelial differentiation programs in EPCs is unknown. Recently, it has been reported that, in patients with type 2 diabetes mellitus and coronary artery disease, circulating CD34 ϩ cells show a drift toward the procalcific versus the endothelial commitment, as evidenced by an increased OC-to-KDR expression ratio. 95 Increased expression of bone-related antigens such as OC and BAP on CD34 ϩ cells has been associated with both osteoporosis 20 and vascular disease. 96 Indeed, the CD34 ϩ OC ϩ cell level correlated with bone mineral density and aortic pulsewave velocity, a measure of vascular stiffness. 20, 96 The presence of erectile dysfunction, another marker of vascular disease, is also associated with a higher expression of OC on circulating EPCs. 97 Moreover, OC-expressing EPCs seem to be regulated by the hormonal status, 98, 99 a finding that supports their involvement in the bone-vascular axis. The reasons for the phenotypic derangement of EPCs in patients at risk for or with established cardiovascular disease are unclear but may be driven by inflammation, as previously suggested in the setting of diabetes mellitus. 77 In vitro, calcification of EPCs can be induced by stimulation of the innate immunity receptors (eg, CD14 and toll-like receptors) by lipopolysaccharide 95 or by treatment with oxidized lowdensity lipoprotein. 100 However, it should be noted that most cultured EPCs used in such studies retain monocytic features. Therefore, acquisition of an osteogenic phenotype of these culture cells should be viewed in light of monocyte plasticity and thus indicates the existence of myeloid calcifying cells (MCCs).
Circulating MCCs
Cells belonging to the myeloid lineage, especially monocyte/ macrophages, show an extreme phenotypic plasticity. For instance, tissue macrophages and, to a lesser extent, circulating monocytes can exist in different forms of activation, namely proinflammatory (M1) and antiinflammatory (M2 or so-called alternatively activated). 101 These phenotypes have different, and sometimes opposing, actions not only on inflammation but also on tissue remodeling and angiogenesis. 102, 103 In addition, monocytes can mimic EPCs in vitro with strong proangiogenic effects in vivo 104, 105 and can differentiate into smooth muscle-like cells. 106 Recently, it has been demonstrated that a fraction of circulating monocytes (Ϸ1% in healthy adults) express BAP (B4 -78 clone) and OC. 107 Freshly isolated human OC ϩ BAP ϩ cells formed spotty calcifications when embedded in Matrigel and implanted subcutaneously in nude mice. 107 The myeloid origin of these cells was confirmed by surface immunophenotype (CD45 ϩ CD14 ϩ CD68 ϩ CD34 Ϫ CD7 Ϫ ) and expression of the BCR-ABL transcript in naïve patients with chronic myeloid leukemia. 107 In addition, these cells did not express the MSC markers CD90, CD44, and CD29 and have been called MCCs. 107 Generation of MCCs, with the expression of OC, BAP, and other bone-related proteins, along with the retention of the myeloid markers CD45, CD14, and CD68, could be recapitulated in monocytes cultured on 2-dimensional Matrigel. 107 Interestingly, OC and BAP expression on circulating monocytes appears to be driven by Runx2, a master gene regulator of osteogenesis. Cultured MCCs display potent procalcific potential when implanted subcutaneously or intramuscularly in immunodeficient mice. 107 Some pathophysiological implications of the existence and activity of MCCs have been shown in relation to diabetic vasculopathy. Patients with type 2 diabetes mellitus have a 2-to 3-fold increased level of circulating MCCs, especially in the presence of atherosclerotic cardiovascular disease, even in the absence of altered markers of bone metabolism. 107 Diabetes mellitus is typically associated with vascular calcification in the form of medial scleral calcification 108 of lower-extremity arteries and spotty intimal calcifications in atherosclerotic lesions. 109, 110 Whereas medial calcification seems attributable mainly to osteogenic transdifferentiation of resident SMCs, 41 circulating calcifying cells (such as MCCs) could be preferentially involved in intimal calcification. Consistently, in carotid atherosclerotic specimens from diabetic patients, OCand BAP-expressing cells were 40% to 50% more frequent in the neointimal areas than in nondiabetic plaques, and there was a direct correlation between the number of OC ϩ BAP ϩ cells and the degree of calcification. 107 The mechanisms that foster MCCs in diabetes mellitus remain unclear, but it is possible that high glucose per se can promote a procalcific phenotypic shift of circulating monocytes by promoting the expression of Runx2, BMP-2, and type 1a collagen. MCCs may also be generated locally with the intrinsically hypoxic neointima because hypoxia was able to upregulate osterix, another important osteogenic gene, and promote calcification by cultured MCCs. From a therapeutic point of view, it appears that the excess levels of circulating MCCs in diabetes mellitus are reversible after optimization of glycemic control, an observation that strengthens the direct link between hyperglycemia and generation/differentiation of MCCs.
The extent to which the phenotype of MCCs overlaps to other procalcific cells remains to be elucidated. For instance, the treatment of cultured monocytes with the cathelicidinderived peptide LL-37 results in the differentiation of large adherent cells that promote the formation of bone-like structures similar to endochondral bone formation when implanted into immunodeficient mice. 111 On detailed immunophenotypic analysis, these cells, called monosteophils, express OC and other bone-related proteins (but not BAP) and are distinct from osteoclasts, macrophages, dendritic cells, and MSCs. Although the status of the research so far does not provide any evidence for circulating monosteophils, cultured MCCs share some degree of homology with these cells from morphological and antigenic perspectives. 107 Rather, the existence of circulating osteoprogenitors within the common leukocyte antigen CD45 ϩ population has been suggested by Egan et al 48 : circulating CD45 ϩ OC ϩ cells (Ϸ1% of circulating mononuclear cells) express type 1 collagen at high frequency and the homing receptor CXCR4, just like MCCs, 107 and promote calcification in vitro. On immunohistochemistry, these cells were present at sites of heterotopic ossification within specimens of diseased aortic valves. Thus, it is possible that BM-derived circulating osteoprogenitors home to the valve leaflets via CXCR4 signaling and contribute to calcification. On the basis of their frequency in the bloodstream, antigenic profile, and local tissue contribution, it is highly probable that these cells overlap with MCCs.
Although osteoclasts can arise from monocytes, it is unknown whether MCCs and bone-resorbing cells share a common precursor. Moreover, whether fully differentiated osteoclasts are actually present within atherosclerotic plaques and contribute to calcification is a matter of debate. Of interest, it has been demonstrated that RANK ligand expres-sion is not essential for vascular SMC calcification but could promote migration of BM-derived macrophages and favor their differentiation into osteoclasts. 112 Whether this effect is present in vivo is unclear, but the demonstration that lack of osteoprotegerin in atherosclerotic mice is associated with increased calcification 113 may suggest a paradoxical procalcific contribution of osteoclast-like cells. 112, 114 These cells may interact with resident calcifying vascular cells through signals similar to those controlling the basic multicellular unit in bone and result in calcium deposition. How MCCs could be involved in this ectopic cooperation is still unclear and represents an interesting matter of investigation.
Pathophysiological and Clinical Implications
The identification of circulating cells harboring an osteogenic potential raises a series of important questions about their pathophysiological role in the bone-vascular axis, their clin- ical significance, and their therapeutic potential (Figure 1) . The pathology of the bone-vascular axis (osteoporosis and vascular calcification) is typically associated with aging and could be accelerated in some clinical conditions such as chronic kidney disease, diabetes mellitus, and chronic obstructive pulmonary disease. 1, 115, 116 A common substrate of these clinical entities is systemic inflammation, which drives bone resorption and promotes vascular disease. 1 The existence of common pathogenic mechanisms allows the possibility of common therapeutic approaches such as lipidlowering strategies. 12, 117 BM-derived cells cooperate with parietal progenitors cells in the normal homeostasis of the vascular/valve tissue. However, perturbation of vascular integrity might induce recruitment and engrafting of BM derived-cells as part of a response to injury. Of note, cell tracking studies were not able to identify a contribution of circulating calcifying cells in medial calcification. 41 On the other hand, a significant participation of circulating calcifying cells in calcium deposition has been described within intimal and valve lesions. 42, 47 In contrast to medial calcification, atherosclerosis and aortic valve calcification share inflammatory mechanisms of disease progression. Together with resident cells, circulating calcifying cells might be recruited and deposit calcium in the tissue in an attempt to resolve the inflammation in the vascular/valve wall. From this perspective, it is not surprising that mesenchymal and hematopoietic phenotypes have been described for these circulating cells 110 (Table 2 and Figure 2 ) because both immune and mesenchymal-derived cells (eg, fibroblasts) are actively involved in the inflammatory response. The significance of calcifying EPCs may be viewed as a sort of endothelial-to-mesenchymal transition phenomenon, driven by inflammatory/profibrotic mechanisms. 80, 118 Thus, it is tempting to speculate that inflammation represents a key link between bone disease, circulating calcifying cells, and vascular pathology.
In contrast to aortic valve stenosis, in which calcification is invariably associated with negative clinical outcomes, the significance of intimal calcification is still controversial. Although microcalcifications can amplify inflammation and destabilize the plaque, extensive calcium deposits have been associated with a stable plaque phenotype. 23 Clarification of the role of circulating calcifying cells in the different phases of atherogenesis is mandatory to establish whether they represent a target for therapeutic interventions. Additional studies are needed to determine their clinical utility for the prediction of future cardiovascular disease because prospective data are currently lacking. It appears that all these aspects are of great relevance to establishing whether circulating calcifying cells could be also used safely for bone-healing interventions. Kuroda and colleagues 119 have reported successful outcomes when using CD34 ϩ cells/EPCs for fracture healing. On the basis of the preclinical study, they have initiated a phase I/IIa clinical trial of autologous local transplantation of granulocyte colony-stimulating factor-mobilized CD34 ϩ cells for patients with tibial or femoral nonunion. The first case exhibited a promising result, but the efficacy of this cell therapy should be further elucidated in a randomized controlled clinical trial.
Conclusions
With the inevitable aging of the general population, it is of paramount importance to identify mechanisms that link together distant end-organ damage caused by the senescence process. Mounting evidence supports the existence of circulating calcifying cells of mesenchymal and hematopoietic origin. By trafficking through the bloodstream, cells with an osteogenic potential are prime candidate regulators of the bone-vascular axis, with potential implications in bone remodeling and vascular calcification. Although the ability of these cells to promote calcification in vitro is established, their activity in vivo is not fully elucidated, especially in relation to vascular biology. Data available so far trace the way for future development of this area of research, which has the potential to identify a novel pathophysiological link between bone and vascular disease and a possible new therapeutic target. Moreover, the exact cell frequency is depicted by the line and the logarithmic y axis scale. A clear overlap exists between CD34 ϩ , endothelial progenitor cells (EPCs), and myeloid calcifying cells. For phenotypic characterization, see Table  2 . PB indicates peripheral blood.
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